CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In CD34+38- CML LSCs, the use of RI-BPI increased the effectiveness of imatinib treatment, and decreased the ability to form CML cell colony, thus eliminated CD34+38- LSCs by enhancing programmed cell death.